Why Voyager Therapeutics Stock Is Sinking Today
Shares of the clinical-stage gene therapy company Voyager Therapeutics (NASDAQ: VYGR) dropped by as much as 11% in pre-market trading Tuesday morning. The biotech's shares are responding negatively to a regulatory delay for its Huntington's disease candidate, VY-HTT01.
After market close yesterday, Voyager announced that the Food and Drug Administration placed a clinical hold on the experimental gene therapy pending the resolution of certain chemistry, manufacturing, and controls (CMC) matters. The company said it expects to receive further details about the hold from the FDA within 30 days.
Image source: Getty Images.
Source Fool.com
